Arteriocyte’s flagship product family, the Magellan® platelet and stem cell separation platform allows surgeons to rapidly prepare concentrated blood products for use in surgery. Other cellular applications under development include proprietary stem cell and tissue based therapies for cardiovascular disease, orthopedic, sports medicine and wound healing applications.

Funding: DW Healthcare Partners, Medtronic, Comerica, Case Technology Ventures, Department of Defense, Significant Grant Funding.

Stage: Commercial

News: Arteriocyte Acquired by Isto Holdings,City of Cleveland’s Small Loan to Arteriocyte Inc. Can Go Long Way